Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHE Alterity Therapeutics	$5.02 -1.6%	$4.74	$1.00 ▼ $7.00	$44.53M	0.67	219,092 shs	13,715 shs
CRBU Caribou Biosciences	$1.85 +0.5%	$1.72	$0.66 ▼ $3.00	$172.27M	2.55	1.34 million shs	1.40 million shs
KRRO Korro Bio	$20.04 -2.5%	$14.70	$10.29 ▼ $98.00	$188.20M	2.51	114,812 shs	148,056 shs
SXTC China SXT Pharmaceuticals	$1.57	$1.68	$0.95 ▼ $7.84	$182.16M	1.24	1.79 million shs	17,398 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHE Alterity Therapeutics	+1.39%	-2.49%	-1.16%	+20.00%	+277.78%
CRBU Caribou Biosciences	+2.22%	-8.00%	-22.36%	+80.39%	-17.49%
KRRO Korro Bio	+6.64%	+3.37%	+44.82%	+48.91%	-55.35%
SXTC China SXT Pharmaceuticals	-1.57%	-0.63%	-10.80%	+1.29%	-77.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATHE Alterity Therapeutics	2.2304 of 5 stars	3.3	5.0	0.6	1.7	0.0
CRBU Caribou Biosciences	2.8281 of 5 stars	3.5	5.0	1.9	1.7	0.0
KRRO Korro Bio	1.3586 of 5 stars	3.6	1.0	1.8	0.0	0.0
SXTC China SXT Pharmaceuticals	0.4464 of 5 stars	0.0	3.0	1.9	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATHE Alterity Therapeutics	2.50	Moderate Buy	$12.00	139.04% Upside
CRBU Caribou Biosciences	3.00	Buy	$6.67	260.36% Upside
KRRO Korro Bio	3.29	Buy	$86.83	333.30% Upside
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ATHE, SXTC, KRRO, and CRBU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	KRRO Korro Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
8/13/2025	KRRO Korro Bio	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Strong-Buy ➝ Strong-Buy	$153.00 ➝ $147.00
8/13/2025	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$100.00 ➝ $90.00
7/24/2025	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	$1.04 per share	N/A
CRBU Caribou Biosciences	$9.99M	17.24	N/A	N/A	$1.78 per share	1.04
KRRO Korro Bio	$6.28M	29.96	N/A	N/A	$12.26 per share	1.63
SXTC China SXT Pharmaceuticals	$1.74M	104.64	N/A	N/A	$21.35 per share	0.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATHE Alterity Therapeutics	-$12.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CRBU Caribou Biosciences	-$149.10M	-$1.78	N/A	N/A	N/A	-1,800.93%	-62.35%	-49.65%	11/5/2025 (Estimated)
KRRO Korro Bio	-$83.58M	-$9.75	N/A	N/A	N/A	N/A	-61.51%	-42.87%	N/A
SXTC China SXT Pharmaceuticals	-$3.30M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest ATHE, SXTC, KRRO, and CRBU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	CRBU Caribou Biosciences	-$0.40	-$0.35	+$0.05	-$0.58	$1.64 million	$2.67 million
8/12/2025	Q2 2025	KRRO Korro Bio	-$2.54	-$2.74	-$0.20	-$2.74	$0.41 million	$1.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
CRBU Caribou Biosciences	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATHE Alterity Therapeutics	N/A	3.84	N/A
CRBU Caribou Biosciences	N/A	6.66	6.66
KRRO Korro Bio	N/A	5.98	5.98
SXTC China SXT Pharmaceuticals	0.01	3.54	3.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATHE Alterity Therapeutics	2.14%
CRBU Caribou Biosciences	77.51%
KRRO Korro Bio	13.18%
SXTC China SXT Pharmaceuticals	5.02%

Insider Ownership

Company	Insider Ownership
ATHE Alterity Therapeutics	38.80%
CRBU Caribou Biosciences	8.28%
KRRO Korro Bio	4.60%
SXTC China SXT Pharmaceuticals	3.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATHE Alterity Therapeutics	10	8.87 million	5.43 million	Not Optionable
CRBU Caribou Biosciences	100	93.12 million	85.41 million	Optionable
KRRO Korro Bio	70	9.39 million	8.96 million	No Data
SXTC China SXT Pharmaceuticals	90	116.03 million	111.45 million	Not Optionable

ATHE, SXTC, KRRO, and CRBU Headlines

Recent News About These Companies

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Up 48.3% in July

August 21 at 9:40 AM | marketbeat.com

Wall Street Zen Upgrades China SXT Pharmaceuticals (NASDAQ:SXTC) to Hold

August 3, 2025 | marketbeat.com

China SXT Pharmaceuticals Full Year 2025 Earnings: US$2.32 loss per share (vs US$28.58 loss in FY 2024)

August 2, 2025 | finance.yahoo.com

China SXT Pharmaceuticals Inc. (SXTC) Stock Price Today - WSJ

July 30, 2025 | wsj.com

China SXT Pharmaceuticals (NASDAQ:SXTC) Trading Down 1.3% - What's Next?

July 30, 2025 | marketbeat.com

China SXT Pharmaceuticals, Inc. (SXTC) - Yahoo Finance

July 4, 2025 | sg.finance.yahoo.com

China SXT Pharmaceuticals Inc News (SXTC) - Investing.com

June 25, 2025 | investing.com

China SXT Pharmaceuticals Issues 90 Million Shares Following Warrant Exercise

June 16, 2025 | tipranks.com

China SXT Pharmaceuticals Inc Ordinary Shares

April 23, 2025 | morningstar.comM

China SXT Pharmaceuticals Reports Financial Results Amid Regulatory Challenges

March 28, 2025 | tipranks.com

China SXT Pharmaceuticals Optimizes Capital Structure with Warrant Exchange

March 19, 2025 | tipranks.com

China SXT Pharmaceuticals regains compliance with Nasdaq

March 17, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency

March 17, 2025 | finance.yahoo.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency

March 17, 2025 | globenewswire.com

China SXT Pharmaceuticals Inc trading resumes

February 25, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, volatility trading pause

February 25, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, news pending

February 24, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Announces New Securities Purchase Agreement

January 27, 2025 | msn.com

China SXT Pharmaceuticals Inc (SXTC) Stock’s 0.02% Increase This Year: What’s the Story?

January 7, 2025 | bovnews.comB

China SXT Pharmaceuticals Inc (SXTC) Stock Price Reaches $0.51: What Factors Are Influencing This Level?

January 1, 2025 | bovnews.comB

China SXT Pharmaceuticals Inc (SXTC) Stock: Greater Than Its Current Valuation?

December 26, 2024 | bovnews.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ATHE, SXTC, KRRO, and CRBU Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

$5.02 -0.08 (-1.57%)

Closing price 03:59 PM Eastern

Extended Trading

$5.04 +0.02 (+0.30%)

As of 04:10 PM Eastern

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Caribou Biosciences NASDAQ:CRBU

$1.85 +0.01 (+0.54%)

Closing price 04:00 PM Eastern

Extended Trading

$1.85 +0.00 (+0.22%)

As of 05:40 PM Eastern

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Korro Bio NASDAQ:KRRO

$20.04 -0.51 (-2.48%)

Closing price 04:00 PM Eastern

Extended Trading

$20.02 -0.02 (-0.07%)

As of 04:10 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.57 0.00 (0.00%)

Closing price 03:55 PM Eastern

Extended Trading

$1.57 +0.00 (+0.25%)

As of 04:12 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time